Heart resynchronization illustrated with precise electrical pathways.

Heart Pacing Revolution: Can MultiPoint Pacing Improve CRT Outcomes?

Mira Elwood in Health & Wellness November 2025 • 3 min read.

"Discover how a new clinical trial is exploring MultiPoint Pacing (MPP) therapy to enhance cardiac resynchronization for heart failure patients."

Heart failure remains a significant health challenge, with a substantial portion of patients not responding adequately to cardiac resynchronization therapy (CRT). CRT aims to improve the heart's efficiency by coordinating the contractions of the left and right ventricles. However, nearly 40% of patients don't experience the full benefits, leading researchers to explore innovative approaches.

MultiPoint Pacing (MPP) has emerged as a promising alternative. This technique involves pacing the heart at multiple points, potentially leading to more coordinated and effective contractions. Early studies suggest that MPP can improve outcomes for some patients, but more rigorous research is needed to confirm these findings.

The MORE-CRT MPP PHASE II trial is designed to provide that evidence. This randomized, multi-center study aims to assess the safety and efficacy of MPP in patients who have not responded to traditional CRT. By evaluating MPP's impact on heart function and overall health, this trial could revolutionize heart failure treatment.

What is MultiPoint Pacing and Why is it Important?

Heart resynchronization illustrated with precise electrical pathways.

Traditional CRT typically involves pacing at one or two points in the heart's left ventricle. In contrast, MPP uses a special lead with multiple electrodes to pace at several locations simultaneously. This multi-point approach may:

This innovative approach seeks to address the limitations of traditional CRT by:

Achieve more synchronized ventricular contractions.
Increase the amount of heart tissue activated during pacing.
Improve the heart's overall efficiency.

MPP's potential to enhance cardiac function has garnered significant attention, leading to the development of the MORE-CRT MPP PHASE II trial to rigorously evaluate its benefits.

The Future of Heart Failure Treatment

The MORE-CRT MPP PHASE II trial represents a crucial step in advancing heart failure therapy. By providing robust evidence on the benefits of MPP, this study could pave the way for a new standard of care, offering hope to the many patients who do not respond to traditional CRT. The results of this trial are eagerly anticipated and may transform the landscape of cardiac pacing.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is MultiPoint Pacing (MPP), and how does it differ from traditional methods?

MultiPoint Pacing (MPP) is a technique used to pace the heart at multiple points simultaneously, using a specialized lead with multiple electrodes. This contrasts with traditional Cardiac Resynchronization Therapy (CRT), which typically paces at only one or two points in the left ventricle. MPP aims to achieve more synchronized ventricular contractions, increase the amount of heart tissue activated during pacing, and improve the heart's overall efficiency. This is particularly important because a significant number of heart failure patients do not respond adequately to traditional CRT. By addressing the limitations of traditional CRT, MPP offers the potential to improve outcomes for these patients.

What is the purpose of the MORE-CRT MPP PHASE II trial, and why is it so important?

The MORE-CRT MPP PHASE II trial is a randomized, multi-center study designed to assess the safety and efficacy of MultiPoint Pacing (MPP) in patients who have not responded to traditional Cardiac Resynchronization Therapy (CRT). The goal is to rigorously evaluate MPP's impact on heart function and overall health. The trial is significant because it represents a crucial step in determining whether MPP can become a new standard of care for heart failure patients who do not benefit from traditional CRT. By providing robust evidence, the trial could transform the landscape of cardiac pacing and offer hope to a substantial portion of patients.

Could you explain what Cardiac Resynchronization Therapy (CRT) is and why it's used?

Cardiac Resynchronization Therapy (CRT) is a treatment that aims to improve the heart's efficiency by coordinating the contractions of the left and right ventricles. This coordination is crucial because, in heart failure, the ventricles often contract in a disorganized manner, reducing the heart's ability to pump blood effectively. CRT typically involves pacing at one or two points in the left ventricle to synchronize these contractions. However, a significant percentage of patients do not respond fully to traditional CRT, which is why alternative approaches like MultiPoint Pacing (MPP) are being explored.

How does MultiPoint Pacing (MPP) enhance cardiac function, and what are the potential benefits?

MultiPoint Pacing (MPP) seeks to enhance cardiac function by pacing the heart at multiple locations simultaneously. This approach is designed to achieve more synchronized ventricular contractions and increase the amount of heart tissue activated during pacing, ultimately improving the heart's overall efficiency. The potential benefits of MPP include better coordination of the heart's contractions, more effective pumping of blood, and improved outcomes for patients who do not respond adequately to traditional Cardiac Resynchronization Therapy (CRT). The MORE-CRT MPP PHASE II trial aims to rigorously evaluate these potential benefits.

What could be the implications if the MORE-CRT MPP PHASE II trial is successful?

If the MORE-CRT MPP PHASE II trial demonstrates the safety and efficacy of MultiPoint Pacing (MPP), it could revolutionize heart failure treatment by establishing MPP as a new standard of care for patients who do not respond to traditional Cardiac Resynchronization Therapy (CRT). This would offer hope to a significant portion of heart failure patients who currently do not experience the full benefits of CRT. The trial's success could lead to wider adoption of MPP, improved patient outcomes, and a transformation in the approach to cardiac pacing.